<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692809</url>
  </required_header>
  <id_info>
    <org_study_id>SKS/LTBI/07</org_study_id>
    <nct_id>NCT00692809</nct_id>
  </id_info>
  <brief_title>Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection</brief_title>
  <acronym>HIV-TB</acronym>
  <official_title>Impact of HIV Infection on Latent TB Among Patients With HIV-TB Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Science and Technology, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV induced altered representation and function of regulatory T cell subsets (NKT and Treg&#xD;
      cells) impair the protective T cell response against M.tuberculosis and disrupts LTBI, thus&#xD;
      facilitates faster progression and development of severe forms of clinical TB in HIV-TB&#xD;
      co-infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the natural course of HIV disease, emergence of opportunistic infection not only&#xD;
      imposes morbidity on HIV-TB co-infected patients, but also facilitates viral replication&#xD;
      causing faster disease progression. Tuberculosis, being the commonest among the opportunistic&#xD;
      infections among HIV infected persons deserves special attention. Moreover, disruption of&#xD;
      latency of TB infection (LTBI) with development of more severe clinical forms at relatively&#xD;
      early stage of HIV disease when CD4 count still remains above 300/ul, makes TB a unique&#xD;
      opportunistic infection and negatively influence the outcome of dual infection.This is&#xD;
      suggestive of impairment of some critical immune function involving relatively less frequent&#xD;
      fine T cell subsets with functional hierarchy over bulk T cells, so as to weaken the immune&#xD;
      containment of LTBI resulting in reactivation of M. tuberculosis and manifestation of severe&#xD;
      forms of TB.HIV has recently been reported to preferentially infect, destroy and incapacitate&#xD;
      two key immune-regulatory T cell subsets, namely NKT and Treg cells.Therefore, studying them&#xD;
      along the course of HIV disease and impact of their changes on the function of effector T&#xD;
      cells directed against M.tuberculosis is important.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Precise component(s) of T cell response against M.tuberculosis compromised by HIV infection which leads to the development of severe forms of clinical tuberculosis.</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elucidation of critical events of the cellular and molecular interactions that would be useful for developing newer therapeutic strategies and vaccination.</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>HIV+ve+LTBI (n=100)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>HIV+ve+clinical TB (n=50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>HIV-ve+clinical TB (n=15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Normal control (n=15)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV+ve+LTBI HIV+ve+clinical TB HIV-ve+clinical TB Normal control&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HIV infected +LTBI group:&#xD;
&#xD;
          -  Patient of either sex between 18-65 years of age&#xD;
&#xD;
          -  All the patients should be HIV ELISA test positive irrespective of CD4 count and&#xD;
             presence of other opportunistic infections Antiretroviral drug naive HIV patients&#xD;
&#xD;
          -  No past history of TB&#xD;
&#xD;
          -  Patients should be either tuberculin test positive (&gt; 5mm) or interferon gamma release&#xD;
             assay positive&#xD;
&#xD;
          -  Written informed consent to participate in the study given by participants or legal&#xD;
             guardian&#xD;
&#xD;
          -  Patients able to comply with instructions and come back for a regular follow up&#xD;
&#xD;
        HIV infected + Clinical TB group:&#xD;
&#xD;
          -  Patient of either sex between 18-65 years of age&#xD;
&#xD;
          -  All the patients should be HIV ELISA test positive irrespective of CD4 count and&#xD;
             presence of other opportunistic infections&#xD;
&#xD;
          -  In PTB group, patient should be two sputum smear positive out of three consecutive&#xD;
             samples&#xD;
&#xD;
          -  In EPTB group, diagnosis of TB will be:&#xD;
&#xD;
               -  Definitive -Culture confirmed&#xD;
&#xD;
               -  Probable -Histopathological or radiological -Clinical features and response to&#xD;
                  anti TB treatment (ATT)&#xD;
&#xD;
               -  Possible TB -Clinical feature and response to anti TB treatment (ATT)&#xD;
&#xD;
          -  Written informed consent to participate in the study given by participants or legal&#xD;
             guardian&#xD;
&#xD;
          -  Patients able to comply with instructions and come back for a regular follow up&#xD;
&#xD;
        HIV negative Clinical TB group:&#xD;
&#xD;
          -  Patients of either sex between 18-65 years of age who are permanent resident of Delhi&#xD;
&#xD;
          -  All patients should be HIV ELISA negative&#xD;
&#xD;
          -  In PTB group, patients should be two sputum smear positive (at least 1+) out of three&#xD;
             consecutive samples&#xD;
&#xD;
          -  In EPTB group, diagnosis of TB will be:&#xD;
&#xD;
               -  Definitive -Culture-confirmed&#xD;
&#xD;
               -  Probable -Histopathological or radiological -Clinical features and response to&#xD;
                  anti-TB treatment (ATT)&#xD;
&#xD;
               -  Possible TB -Clinical features and response to anti-TB treatment (ATT)&#xD;
&#xD;
          -  Written informed consent to participate in the study given by participants or legal&#xD;
             guardian&#xD;
&#xD;
          -  Patients able to comply with instructions and come back for a regular follow up&#xD;
&#xD;
        Normal controls:&#xD;
&#xD;
          -  Persons of either sex between 18-65 years of age who are permanent resident of Delhi&#xD;
&#xD;
          -  Written informed consent to participate in the study given by participants or legal&#xD;
             guardian&#xD;
&#xD;
          -  Person should not have past history of TB&#xD;
&#xD;
               -  Mantoux test negative (&lt; 10mm)&#xD;
&#xD;
               -  Chest-X-ray normal&#xD;
&#xD;
               -  Hemogram normal&#xD;
&#xD;
          -  Renal and liver functions normal&#xD;
&#xD;
          -  Hepatitis viral markers normal&#xD;
&#xD;
          -  No clinical evidence of malnutrition&#xD;
&#xD;
          -  HIV ELISA negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        HIV infected +LTBI group:&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  Patients who are getting steroid therapy&#xD;
&#xD;
          -  Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver&#xD;
             diseases&#xD;
&#xD;
          -  Currently receiving cytotoxic therapy, or have received it within the last 3 months&#xD;
&#xD;
          -  Terminally ill as per treating clinician's judgment&#xD;
&#xD;
          -  Patient from outside Delhi and migrants&#xD;
&#xD;
        HIV infected + Clinical TB group:&#xD;
&#xD;
          -  Category II and multidrug-resistant pulmonary tuberculosis&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  Patients who are getting steroid therapy&#xD;
&#xD;
          -  Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver&#xD;
             diseases&#xD;
&#xD;
          -  Currently receiving cytotoxic therapy, or have received it within the last 3 months&#xD;
&#xD;
          -  Terminally ill patient as per treating clinician's judgment&#xD;
&#xD;
          -  Patients from outside Delhi and migrants&#xD;
&#xD;
        HIV negative Clinical TB group:&#xD;
&#xD;
          -  Category II and multi drug-resistant pulmonary tuberculosis&#xD;
&#xD;
          -  Patients who are getting steroid therapy&#xD;
&#xD;
          -  Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver&#xD;
             disease&#xD;
&#xD;
          -  Currently receiving cytotoxic therapy, or have received it within the last 3 months&#xD;
&#xD;
          -  Terminally ill patient as per treating clinician's judgment&#xD;
&#xD;
          -  Patients unwilling to comply with the study procedures or those with history of&#xD;
             alcohol or drug abuse&#xD;
&#xD;
        Normal controls:&#xD;
&#xD;
          -  Transplant patients, diabetes mellitus or malignancy&#xD;
&#xD;
          -  Patients unwilling to comply with the study procedures or those with history of&#xD;
             alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surendra K Sharma, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surendra K Sharma, M.D., Ph.D</last_name>
    <phone>26594415</phone>
    <email>surensk@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110608</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surendra K Sharma, M.D., Ph.D</last_name>
      <phone>26594415</phone>
      <email>surensk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanjeev Sinha, MD</last_name>
      <phone>26594440</phone>
      <email>drsanjeevsinha2002@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Surendra K Sharma, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjeev Sinha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dipender K Mitra, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amit K Dinda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. S.K. Sharma, Professor &amp; Head</name_title>
    <organization>All India Institute of Medical Sciences</organization>
  </responsible_party>
  <keyword>Latent tuberculosis infection</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Natural Killer T Cells</keyword>
  <keyword>Invariant Natural Killer T Cells</keyword>
  <keyword>Regulatory T cells</keyword>
  <keyword>Interferon-gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

